Rybrevant (amivantamab)
pCPA File Number:
23558
Negotiation Status:
Concluded with an LOI
Indication(s):
Non-small cell lung cancer (NSCLC), Locally advanced or metastatic, in adult patients with activating epidermal-growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on, or after platinum-based chemotherapy
Sponsor/Manufacturer:
Janssen Inc.
CDA-AMC Project Number:
Not Applicable
pCPA Engagement Letter Issued:
Negotiation Process Concluded: